Development of Tr1 cell-inducing exosome for early remission of allergies

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K15280
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47040:Pharmacology-related
• Research Institution: Setsunan University
• Principal Investigator: Matsuda Masaya 摂南大学, 薬学部, 助教 (30783005)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: アレルギー / エクソソーム / Tr1細胞 / 細胞外小胞

Outline of Final Research Achievements

If it is possible to induce antigen-specific type 1 regulatory T (Tr1) cells in the body, early remission of allergies can be expected. Therefore, in this study, we focused on exosomes, a type of extracellular vesicle, and aimed to create exosomes carrying Tr1 cell-inducing factors (IL-27, IL-21, and TGF-β). We achieved the following results: (1) We transfected the genes of the Tr1 cell-inducing factors into DC2.4, a mouse dendritic cell line, and established a cell line with high expression of Tr1 cell-inducing factors. (2) Exosomes produced from the cell line with high expression of Tr1 cell-inducing factors contained IL-27, but the presence of IL-21 and TGF-β was not detected.

Free Research Field

アレルギー、薬理学

Academic Significance and Societal Importance of the Research Achievements

本申請課題の手法では、IL-27以外のTr1誘導性サイトカインの含有は認められなかったため、今後培養方法などを改良する必要がある。生体内においてTr1細胞を効率よく誘導することができれば、アレルギーを早期根治に導く新規治療薬の開発につながることが期待される。